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Abstract: Regenerative medicine is extensively interested in developing cell therapies using
mesenchymal stem cells (MSCs), with applications to several aging-associated diseases. For successful
therapies, a substantial number of cells are needed, requiring extensive ex vivo cell expansion.
However, MSC proliferation is limited and it is quite likely that long-term culture evokes continuous
changes in MSCs. Therefore, a substantial proportion of cells may undergo senescence. In the present
review, we will first present the phenotypic characterization of senescent human MSCs (hMSCs)
and their possible consequent functional alterations. The accumulation of oxidative stress and
dysregulation of key differentiation regulatory factors determine decreased differentiation potential
of senescent hMSCs. Senescent hMSCs also show a marked impairment in their migratory and homing
ability. Finally, many factors present in the secretome of senescent hMSCs are able to exacerbate the
inflammatory response at a systemic level, decreasing the immune modulation activity of hMSCs
and promoting either proliferation or migration of cancer cells. Considering the deleterious effects
that these changes could evoke, it would appear of primary importance to monitor the occurrence of
senescent phenotype in clinically expanded hMSCs and to evaluate possible ways to prevent in vitro
MSC senescence. An updated critical presentation of the possible strategies for in vitro senescence
monitoring and prevention constitutes the second part of this review. Understanding the mechanisms
that drive toward hMSC growth arrest and evaluating how to counteract these for preserving a
functional stem cell pool is of fundamental importance for the development of efficient cell-based
therapeutic approaches.
Keywords: mesenchymal stem cells; senescence; differentiation potential; immunoregulatory activity;
migratory ability; tumour-promoting function
1. Introduction
The maintenance and repair of adult tissues and organ are guaranteed by the adult stem cell
pool. Among adult stem cells, mesenchymal stem cells (MSCs) are emerging as hopeful candidates for
cell-based therapy of numerous diseases.
Human MSCs (hMSCs) are non-hematopoietic cells capable of self-renewal and multi-lineage
differentiation into various tissues of mesodermal origin. These cells can be easily isolated and
expanded from the stroma of virtually all organs, although the preferred sources are bone marrow
and subcutaneous fat [1]. Upon isolation, hMSCs are characterized by their capability to adhere to
plastic, develop as fibroblast colony-forming-units, and differentiate into osteocytes, chondrocytes,
and adipocytes. After in vitro culture expansion, hMSCs are positive for CD73, CD90, and CD105 and
negative for CD11b, CD14, CD34, CD45, and HLA-DR [2]. In addition to their robust differentiation
Int. J. Mol. Sci. 2016, 17, 1164; doi:10.3390/ijms17071164 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 1164 2 of 18
potential, hMSCs have a remarkable capacity of inhibiting the immune response, an activity known
generally as immunomodulation or immunoregulation [3]. This hMSC immunoregulatory capacity
includes B and T cell proliferation inhibition, cytokine production inhibition, together with decreased
NK cell activation, and dendritic cell maturation. By taking advantage of these features, hMSCs have
been used successfully in several experimental models for allogeneic transplant rejection prevention
and autoimmune/inflammatory disorders treatment. Notably, most of the beneficial effects mediated
by hMSC cell therapy involved the broad repertoire of secreted trophic factors (commonly referred to
as the MSC secretome) exhibiting diverse functions such as immunomodulation, anti-inflammatory
activity, angiogenesis regulation, and anti-apoptotic activity. Due to their high proliferative potential,
multipotency, paracrine effect, and immunomodulatory activity, MSCs are ideal candidates for
regenerative medicine and immunotherapy [4,5]. Indeed, MSCs are the major stem cells for cell therapy
and in the last decade have been used in the clinic to treat a variety of traumatic and degenerative
disorders [6].
Cultured primary cells do not grown infinitely, but undergo only a limited number of cell division,
in a process called cellular senescence [7], and hMSCs make no exception. Although hMSCs are
present in several tissues, they are scarce in the body. For this reason cell therapy protocols generally
require hundreds of million hMSCs per treatment and, consequently, these cells need to be expanded
in vitro for about 10 weeks before implantation (http://www.clinicaltrials.gov). Notably, patient’s
clinical history, age, and genetic makeup strongly influence the length of this expansion period and
the quality of the obtained cells [8,9]. Aged MSCs generally perform less well than their younger
counterparts in various disease models (reviewed in [10]) and mounting evidence strongly suggests
that cellular senescence contribute to aging and age-related diseases. In particular, the factors that
senescent cells secrete affect vital and tightly-regulated processes, such as cell growth and migration,
tissue architecture, blood vessel formation, and differentiation. The inappropriate presence of these
factors can disrupt tissue structure and function. Among the secreted factors, there are also several
potent inflammatory cytokines. Chronic inflammation is a hallmark of aging that initiates or supports
most major age-related diseases. Chronic inflammation and the strong oxidants produced by some
immune cells can affect cell and tissue quality tissues because some immune cells produce strong
oxidants. In addition, other factors secreted by the immune cells further alter and remodel the tissue
enviroment, promoting cell/tissue dysfunction and stem cell niche impairment. Oxidatine damage and
the general inflammatory milieu can also initiate carcinogenesis and promote cancer by suppressing
immune surveillance and stimulating malignant phenotypes (reviewed in [11–13]).
Due to the prolonged expansion regimens that are needed in the clinic to obtain sufficient amounts
of hMSCs for therapy, and based on the patient-specific quality of cells, it is quite likely that long-term
culture evokes continuous changes in hMSCs. In particular, a substantial proportion of cells may
undergo senescence [14]. It would, thus, be of great significance to monitor the occurrence of a
senescent phenotype in hMSCs addressed to clinical uses and to evaluate the functional consequences
of senescence in hMSCs which could affect their clinical therapeutic potential, taking into account their
paracrine effects, immunomodulatory activity, differentiation potential, and cell migration ability [14].
2. Senescence Activation in hMSCs and Phenotypic Characterization
Both exogenous and endogenous factors constantly stress and damage cells, including stem
cells. Additionally, to either complete recovery and cell survival or cell death, proliferating
cells can undertake a third response by adopting a state of permanent cell-cycle arrest, termed
cellular senescence.
Cellular senescence was formally described in the 1960s when Hayflick and colleagues showed
that human diploid fibroblasts had a limited ability to proliferate in culture [7]. Subsequently,
it was demonstrated that mitotically-competent cells respond to many other stressors by undergoing
cellular senescence. These stressors include dysfunctional telomeres, genotoxic stresses/DNA damage,
perturbations to chromatin organization, and strong mitogenic signals. Notably, activation of the DNA
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damage response (DDR) pathways is involved in both the induction and maintenance of senescence
in many cases. In this way, cellular senescence can be regarded as a permanent DNA damage
response activation. Shortening telomeres produces a persistent DDR, which activates and sustains
the senescence growth arrest [15–19]. DNA double-strand breaks are specifically potent senescence
activators [20]. In addition, compounds which relax chromatin without substantially damaging DNA,
such as histone deacetylase inhibitors, activate the DDR proteins Ataxia Telangiectasia Mutated (ATM)
and the p53 tumour suppressor [21], and induce a senescence response [22,23]. Finally, strong mitogenic
signals, such as those delivered by certain oncogenes or highly-expressed pro-proliferative genes can
induce cells to senescence [24–26]. In this case misfired replication origins and replication fork collapse
are causative of DNA damage and a persistent DDR. [27–29]. Thus, many senescence-inducing stimuli
cause epigenomic interference or genomic damage.
At the molecular level, senescence is triggered by the retinoblastoma protein (Rb) or p53 pathways,
which activate the cyclin-dependent kinase inhibitors p16 and p21, respectively. Notably, the pathways
can act on each other and cooperate to induce senescence [30–32].
Senescent cells undergo irreversible growth arrest but continue to be metabolically active and
develop a large, flat morphology, display characteristic changes in gene expression, typically exhibit
a senescence-associated β-galactosidase (SA-β-gal) activity, harbour characteristic enlarged and
persistent DNA damage nuclear foci (PDDF) that contain DDR proteins, including γH2AX and 53BP1,
and accumulate a distinct heterochromatin structure, termed senescence-associated heterochromatin
foci (SAHFs) [19]. In addition, senescent cells secrete a myriad of factors, including growth factors,
proteases and cytokines, with potent autocrine and paracrine activities [33–37]. Some of the biological
features of senescent cells can be explained by this senescence-associated secretory phenotype (SASP).
Human MSCs have been reported to be highly resistant to apoptosis induced by different
genotoxic insults [38–41] and preferentially respond to injury with activation of stress-induced
premature senescence (SIPS). Wang et al. published the first comprehensive phenotypic (and mechanistic)
study of X-ray induced senescence in hMSCs [42]. Ten days after irradiation, the majority of the cells
became enlarged, flattened, and stained positive with SA-β-gal. Analysing expression profiles of
Rb, p53, p21, and p16, they confirmed IR-induced hMSC senescence, highlighting that the critical
transition occurred between days 3 and 6. In particular, their results suggested that p53-p21 pathway
played a key role in IR-induced cell cycle arrest as shown previously [43], whereas the the Rb-p16
pathway might play a more important role in IR-induced full senescence of hMSCs. Additionally, they
partially described the hMSC SASP phenotype, reporting significant upregulation of Growth Related
Oncogene (GRO), IL8, IL12, and Macrophage-Derived Chemokine (MDC). Finally, they characterized
the cytoskeletal reorganization of hMSC, describing a reduction of myosin-10, redistribution of
myosin-9 and secretion of profilin-1 and demonstrating that Ck2 was a crucial kinase involved in this
reorganization [42].
Senescence activation in hMSCs was described in some other papers, using hMSCs from different
sources, such as dental pulp [44–46], cord blood [47], and endometrium [48,49]. Human MSCs
respond with a senescence program following different stresses, including oxidative stress [49,50],
heat shock [48], and chemotherapeutic agents [46,51,52]. These works demonstrated that the senescence
activation pathway and resulting profile are independent of the tissue source and the stress stimuli.
They also added some details in hMSC senescence characterization. In particular, analogously to
human fibroblasts [18], hMSC senescence was sustained by persistent DDR activation, as highlighted by
the presence of characteristic enlarged (PDDF), containing γH2AX and 53BP1 foci [44,46,51] (Figure 1).
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Figure 1. Phenotypic characterization of senescent hMSCs. Senescent hMSCs activate p53/p21 and 
Rb/p16 pathways to block the cell cycle and sustain growth arrest. Senescent hMSCs are characterized 
by a specific SASP and by the presence of persistent DNA damage foci, containing γH2AX and 53BP1, 
and are positive for SA-β-gal.  
Additionally, Sepulveda et al. characterized in details the SASP activated in senescent hMSCs 
and measured global gene expression changes following senescence induction [53]. Senescent hMSCs 
secreted higher levels of numerous proteins compared to non-senescent cells: they identified 27 
proteins that were over-secreted by senescent cells in comparison to non-senescent cells. Among the 
factors that reached the highest levels of secretions, they reported LEPTIN, Transforming Growth 
Factor Alpha (TGFA), IL8, EOTAXIN, Interferon Gamma (IFNG), VCAM1, Interferon Beta (IFNB), 
IL4, and Monocyte Chemotactic Protein-1 (MCP1). Notably these factors are relevant for their ability 
to exacerbate the inflammatory response at a systemic level (Figure 1). In accordance with previous 
reports [54,55], genome expression profile analysis detailed more than 5000 genes, including 31 
miRNAs, differentially expressed in senescent hMSCs compared to control cells. These genes affect 
several cellular functions, including cell growth and proliferation, cell cycle, cell death, and cellular 
movement. Considering miRNA expression profile, it was reported an upregulation of the miR-34 
family, which had been previously demonstrated to to be regulated by p53 and to induce cell 
senescence [56,57]. In contrast, the miR-17 group was downregulated in senescent cells, analogously 
to the decreased expression observed in human aging [58]. 
In addition to SIPS, replicative senescence has been widely studied in hMSCs, particularly for 
its clinical implications. Once in culture, hMSCs undergo replication senescence, by some estimates 
between 50 and 90 days post-harvest [59]. Mechanisms and molecular pathways leading to hMSC 
replicative senescence are analogous to those involved in SIPS. p16, p21, and p53 are among the 
senescence-related genes upregulated in long-term culture [60]. The tumour suppressor Rb genes 
have also been shown to play a role in hMSC senescence [61]. Specific changes in gene expression 
have been observed during long-term MSC culture. Generally, these changes included 
downregulation of genes related to differentiation, focal adhesion organization, cytoskeletal 
maintenance, and mitochondrial function [52]. 
3. Functional Alterations in Senescent hMSCs 
Many reports investigated the effect of hMSC senescence on migratory ability, differentiation 
potential, immunomodulation ability, and tumor progression. 
With senescence, hMSCs exhibited decreased differentiation potential and the balance between 
differentiations to the osteogenic versus adipogenic lineages was disrupted, although the direction 
of this shift is still controversial. Some studies indicated that the osteogenic activity of hMSCs 
deteriorated progressively as a function of increasing lifespan [62]. On the other hand, there were 
numerous reports in which the osteogenic potential in late passage MSCs was preserved or even 
increased [54,63,64]. Accumulation of oxidative stress and dysregulation of key differentiation 
regulatory factors such as Runx2, C/EBPα, and PPARγ [60,65] appeared to be crucial in this balance 
loss. Disagreement about whether senescent MSCs are more or less osteogenic is likely an effect of 
differing culture conditions and the lack of optimal in vitro assays to fully characterize osteogenesis. 
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whether senescent MSCs are more or less osteogenic is likely an effect of differing culture conditions
and the lack of optimal in vitro assays to fully characterize osteogenesis. For example, increased
cell death can determine a higher degree of alizarin red staining, providing the false suggestion of
enhanced osteogenic differentiation. In one well-controlled study employing a rat model, long-term
cultured MSCs revealed a great in vitro differentiation potential impairment, with complete loss of
osteogenic potential and diminished adipogenic potential [55] (Figure 2).
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demonstrated that radiation-induced senescence abrogated the hMSC protective immunoregulatory 
function effect in a mouse model of sepsis. On one hand, senescent hMSCs retained an aptitude to 
regulate the inflammatory response on macrophages in vitro and, in part, retained their ability to 
inhibit lymphocyte proliferation, but on the other hand they had a severely reduced migratory 
capacity in response to proinflammatory signals, which was associated with an inhibition of the AP-
1 pathway. Notably, many of the SASP components over-secreted by senescent hMSCs are associated 
to the immune system process. For example, IL8 induces chemotaxis in neutrophils and other 
granulocytes [66], and is a potent promoter of angiogenesis [67]. VCAM1 mediates leukocyte-
endothelium adhesion, and elevated levels of circulating soluble form has been related to systemic 
inflammation disease, such as systemic lupus erythematosus and coronary artery disease [68,69]. 
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Figure 2. Functional alterations occurring in senescent hMSCs. Senescent hMSCs exhibit impaired
differentiation potential, altered immunoregulatory activity, reduced migratory, and homing ability,
and increased tumour-promoting functions.
Recently, Sepulveda et al. addressed how cellular senescence influences the therapeutic potential
of hMSCs, testing their immunoregulatory activity in vitro and in vivo [53]. Data demonstrated
that radiation-induced senescence abrogated the hMSC protective immunoregulatory function
effect in a mouse model of sepsis. On one hand, senescent hMSCs retained an aptitude to
regulate the inflammatory response on macrophages in vitro and, in part, retained their ability to
inhibit lymphocyte proliferation, but on the other hand they had a severely reduced migratory
capacity in response to proinflammatory signals, which was associated with an inhibition of the
AP-1 pathway. Notably, many of the SASP components over-secreted by senescent hMSCs are
associated to the immune system process. For example, IL8 induces chemotaxis in neutrophils
and other granulocytes [66], and is a potent promoter of angiogenesis [67]. VCAM1 mediates
leukocyte-endothelium adhesion, and elevated levels of circulating soluble form has been related
to systemic inflammation disease, such as systemic lupus erythematosus and coronary artery
disease [68,69]. Finally, MCP1 (CCL2) is a chemoattractant for monocytes nd basophils and has an
important role in several inflammatory diseases, such as mul ple scl rosis [70] and inflammatory owel
disease [71]. These data strongly support th idea that in vivo admin str tion of senes ent hMSCs
could exacerbate the inflammatory respo se at a s stemic level and counter ct the an i-inflammatory
effect of these cells as measured in vitro. Understanding the physiol gical and pathological
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factors that influence the immune modulatory activity of hMSCs is of great importance, for both
autoimmune/inflammatory disorders and degenerative pathologies. Indeed, recent data clearly
demonstrated that the regenerative capabilities of transplanted MSCs in damaged tissues, such
as infarcted myocardium, mainly reside in their paracrine activity, instead of their potential for
differentiation into specific cell lineages [72,73] (Figure 2).
For an effective therapeutic approach based on MSCs, a proper cell migration towards relevant
stimuli is crucial for functional engraftment. In the previously described paper by Sepulveda et al. [53],
a migratory defect in senescent hMSCs was associated with their altered immunomodulation ability.
The authors demonstrated a close association of AP-1 pathway inhibition with the impaired response of
senescent hMSCs to migratory stimuli. Measuring the expression of the AP-1 components FOS and JUN
(and their phosphorylated forms) after application of a migratory stimuli (macrophage-conditioned
medium), they found that senescent hMSCs showed a marked decrease in the expression of these
proteins. To further confirm the relation between defective AP-1 activation and migratory impairment,
they evaluated FOS expression in an in vitro wound-healing assay, and observed that the majority
of presenescent wound-edge cells showed a high FOS expression soon after the scraping of the cell
monolayer, whereas senescent wound-edge hMSCs exhibited weak FOS levels at the same time
point [53]. In a subsequent paper, authors correlated miR-355 increase in senescent hMSCs with AP-1
activity inhibition [74]. Many other papers reported that MSCs lost their migratory and homing ability
during in vitro expansion culture, albeit most of these data referred to murine models [55,75–77].
Rombouts et al. showed that primary bone marrow derived MSCs were able to efficiently home
and expand in both spleen and bone marrow in an irradiated syngeneic mouse model. Differently,
in vitro-expanded MSCs rapidly lost their in vivo homing ability [77]. Geissler et al. assessed in vitro
migration potential of rat MSCs after long-term cultivation and described a significantly decreased
migration rate of in vitro aged MSCs compared to their primary counterparts [55]. A transcriptome
analysis revealed that genes involved in focal adhesion organization and cytoskeleton turnover were
downregulated in long-term cultured MSCs [55]. Notably, cellular migration strongly depends on
local cytoskeleton organization and actin turn-over [78] and the impact of local actin organization for
migration is accented by the importance of lamellipodia, fillopodia and focal complex formation for
cellular migration [79]. Declining maintenance of the cytoskeleton and focal adhesion machinery was
observed with serial MSC passaging [80]. On the molecular level, a downregulation of mRNAs for
several chemokines, cytokines, and their receptors relevant for cell migration was observed during
in vitro aging, e.g., stromal cell-derived factor 1 (SDF-1) and its receptor Chemokine Receptor Type 4
(CXCR4) [55]. Studies investigating skeletal repair and systemic skeletal disorders in animal models
showed that CXCR4 and SDF-1 recruited MSCs to the fracture site and prevented bone loss [81].
Changing in the MSC surface markers during prolonged cultivation was reported to be related with
decreased homing ability of hMSCs [76]. In particular, the authors described a strong decrease in
VCAM1 expression, an important mediator of MSC interaction with endothelial cells and subsequent
MSC homing (Figure 2).
Despite senescence-induced growth arrest being a potent cell-autonomous tumour suppressor
mechanism, the associated SASP, altering the behaviour of neighbouring cells and the quality of tissue
environments, exerts cell-non-autonomous effects than can be either beneficial or detrimental [82].
The SASP has been shown to promote the proliferation of pre-malignant and malignant epithelium [83],
enhance invasion [84], induce an epithelial to mesenchymal transition in carcinoma cells [85], increase
the growth of xenograft tumors in vivo [86], and mediate paracrine transmission of senescence [87].
Nevertheless, all of these studies were conducted on senescent fibroblasts. On the other hand, it is
well documented that MSCs can also play tumour-promoting functions [88–90]. Additional effects of
senescence on MSC tumour-promoting functions were investigated and the available data highlighted
the ability of senescent hMSCs to further promote either proliferation or migration (or both) of cancer
cells [51,52,91,92]. Skolekova et al. demonstrated that senescent hMSCs, secreting high amount of IL6
and IL8, were able to increase the resistance of breast cancer cells to cisplatin, favoured the appearance
of cancer stem-like cells in vitro, and increased cisplatin resistance and tumour volume in vivo [52].
The importance of IL6 as a principal mediator for the tumour-promoting activity of senescent hMSCs
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was also evidenced by Di et al., who demonstrated that its secretion stimulated the proliferation
and migration of breast cancer cells in vitro and, notably, did so in vivo in a co-transplant xenograft
mouse model [92]. In accordance with these data, we found recently a robust increase of several
inflammatory cytokine genes in senescent hMSCs [51], including IL6, IL8, the chemokine GRO1,
MCP-2 and RANTES, the inflammatory factor Granulocyte-Macrophage Colony-Stimulating Factor
(GM-CSF), the metalloprotease MMP3 and the adhesion molecule Intercellular Adhesion Molecule 1
(ICAM). These senescent hMSCs, by altering their secretory profile, enhanced the in vitro migration of
two solid tumour-derived cell lines [51]. In another work, galectin-3 was among the factors secreted
by senescent adipose-derived MSCs that could promote tumourigenesis [91]. Galectin-3 is a member
of a family of β-galactoside binding proteins and has emerged as an important regulator of diverse
functions critical in cancer biology, supporting chemoresistance and metastasis in solid tumours,
as well as in leukaemia and lymphoma [93] (Figure 2).
Overall, these data suggest that SASP increases the complexity of paracrine communication
among hMSCs and their physiological/pathological microenvironment, further enhancing their
tumour-promoting behaviour. A greater understanding of the molecular mechanisms involved in
the senescence of hMSCs and careful investigation of the interconnection among senescent and naïve
hMSC secretory phenotypes will provide valuable new insights to comprehend the link with this
cancer-promoting behaviour.
4. Tools to Monitor hMSC Senescence in Vitro
There is a growing perception that standardized protocols and quality control of therapeutic cell
preparations are a prerequisite for reliable and reproducible cellular therapy and that these should
include cellular senescence assessment. Different methods have been tested to track hMSC senescence,
with the specific aim to identify potential quantitative markers for pre-evaluating the clinical efficacy
of individual hMSC preparations in clinical application (Table 1).
Table 1. Methods to monitor changes in senescent hMSCs.
Method Advantages Limits REF.
Phenotypic changes evaluation
Number of passage
Simple and easily documented. Seeding density and
confluence degree variations
between laboratories
[94–97]Good indicator for long-term culture under
standardized conditions
Cumulative
population doublings
Robust parameter for comparison between
different laboratories
Big variations between
different samples [98]
SA-β-galactosidase Almost specific senescent marker.Fast and easy method
Difficult quantitative analysis.
Inability to detect early
senescent cells
[54,99]
Telomere length
Direct measure for prospective analysis of
potential cell division.
Stress-induced senescence
might be independent of
telomere shortening
[100]Availability of several techniques to
quantify telomere length
Cytogenetic techniques
Karyotype Tumorigenic mutations and potentiallyimmortalized cell clones may be detected
Minor genomic losses or gains
may not be detected [101–104]
CGH array More sensitive technique
Inability to reveal balanced
translocation or very
small mutations
[105,106]
Genomic and epigenomic analyses
Gene expression
markers
Fast and reliable quantification based on
microarray techniques. Cross-validation enrolling
different MSC preparation
is needed
[107–111]Panels of up- and down-regulated genes may be
more robust than individual markers
DNA methylation
Senescence-associated DNA-methylation
changes are highly reproducible. Cross-validation enrolling
different MSC preparations
is needed
[112–115]Identification of an Epigenetic-Senescence-Signature
based on six specific CpG sites to estimate
the state of cellular aging
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At a first glance, one of the most convenient predictive indicators of replicative senescence
in vitro would appear to be the number of cell passages. However, as there is great variation both
in seeding densities and time of harvesting [94–97], passage numbers may lead to deceptive results
under non-standardized conditions. To evaluate the number of cumulative population doublings (PD)
should overcome these limitations [98]. Yet, analysis of PD does not consider the probable events of
cells lost for apoptosis, necrosis or during passaging. More importantly, there are large variations
between different donor samples. Taken together, these data suggest it to be hard to predict at which
passage or number of cell divisions MSCs are approaching a senescent state.
A popular hystochemical approach is to stain the senescent cells based on the accumulation of
SA-β-gal. The staining procedure is easy and reliable but the results can hardly be quantified and
almost exclusively the enlarged, late senescent cells stain positive for SA-β-gal [54,99], precluding
detection of the early senescent cells. In addition, SA-β-gal is not required for manifestation of
senescence. Despite these limitations, SA-β-gal staining is presently the most widely used biomarker
for senescent cells.
Telomere length decrease may serve as another possible indicator for mitotic history and
the prospective additional life span [100,116]. However, stress induced senescence may occur
independently of cell division and telomere shortening and it needs to be demonstrated if quantitative
analysis of telomere length facilitates reliable and prospective quality control with regard to
cellular aging.
A still debated theme concerns the genetic stability of in vitro expanded hMSCs and how
it could drive hMSC towards a senescence phenotype. It has been shown that hMSCs do not
transform spontaneously in vitro and chromosomal instability and cytogenetic aberrations occur
without leading to malignant transformation [101,102]. It is becoming more accepted that all ex
vivo hMSC expansion procedures favour the accumulation of aneuploid cells, which is intimately
associated with the progression of senescence [101,103,104,117]. Anyway, the observed cytogenetic
aberrations prompted to evaluate conventional karyotyping and CGH array (complete genome
hybridization-array) approaches as a further ways to monitor hMSCs senescence [105,106]. However,
through conventional karyotyping minor genomic gains or losses may not be detected, while the
more sensitive CGH array technique is incapable of revealing balanced translocations or very
small mutations. More importantly, there are presently no clearly-described karyotype markers
for cellular aging.
Considering the limitations highlighted for these previously described methods, based on either
phenotypic or cytogenetic changes that occur in senescent hMSCs, more recently novel efforts
were turned towards evaluation of either gene expression or DNA methylation changes during
long-term cultures.
Replicative senescence-associated gene expression changes in hMSCs, isolated in two different
laboratories and grown under different culture conditions, were analysed with different microarray
platforms [107]. Despite these methodological differences, there was a high resemblance in
senescence-associated gene expression signatures. Authors found senescence-associated upregulation
of PTPL1-associated RhoGAP 1 (PARG1) and cyclin-dependent kinase inhibitor 2B (CDKN2B)
and down-regulation of pleiotrophin (PTN) mini-chromosome maintenance complex component 3
(MCM3) [107]. To validate these result, they performed quantitative RT-PCR analysis of these
four genes in other five different types of MSC preparations and long-term cultures from different
laboratories [108]. Despite confirming the described differences between early and late passages,
standard deviations were rather high, impeding distinguishing senescent MSCs clearly.
In a more recent paper, hMSCs derived from six different donors, grown under identical culture
conditions and harvested at cell passages 3, 5, and 7, were analysed with gene-expression profiling by
using microarray technology [109]. Their analysis revealed a set of 78 genes that significantly differ
in expression between the first and the last passage analysed. When the significant gene lists were
analysed through pathway analysis, almost 40% of these genes turned out to be involved cellular
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growth, proliferation, and cellular development. Notably, this gene expression profile of senescent
MSC suggests that extensively cultured MSCs seem to be undergoing differentiation. These results
identified specific gene markers to distinguish in vitro aged MSCs [108].
Other similar investigations involved gene-expression profiling of human MSCs derived from
bone marrow upon long-term culture. Kulterer et al. reported that 838 genes were differentially
expressed between P2 and P5, with as few as 10 genes matching those identified in Ballayr study
(BST1, COL11A1, COL12A1, GALNT5, HAS1, KRT18, MEG3, PCM1, PENK, and SHB) [110]. Likewise,
in another study by Tanabe et al., only two reported genes matched those found in Ballayr paper
(KRT18 and PRDX4) [111]. A number of reasons exist for these discrepancies from a biologic standpoint,
including culture conditions, media used, and the source of MSCs.
Further specification of senescence-associated markers and cross-validation in different MSC
preparations are needed for a reliable quality control of cell preparations based on gene expression
level. Additional work is necessary to determine whether the expression of identified gene markers is
consistently modulated when cellular expansion is scaled up by using bioreactors or performed with
different substrates and media components. Discovering genes expressed in MSCs that correlate with
a functional outcome will provide a basis for a set of quality markers. These quality markers can then
be used to assess cellular products desired for a specific application. These are major considerations in
establishing quality, function, and safety of MSCs for therapeutic purposes.
Additionally, through whole genome expression profiling, it was demonstrated that DNA
methylation profiles are clearly affected by long-term culture [112]. Culture expansion of MSCs
is associated with senescence-associated DNA-methylation (SA-DNAm) changes at specific promoter
regions, which become either hyper-methylated or hypo-methylated [105,112,113]. These reports
evidenced that in long-term culture hypermethylation increases at genes related to DNA replication,
cell cycle regulation, DNA repair, adipogenic differentiation, and several metabolic processes, such as
genes for lipid and fatty acid metabolic process. Importantly these data highlighted that SA-DNAm
changes are highly reproducible and may therefore be used to monitor cellular senescence. To this
end, Wagner group elaborated an Epigenetic-Senescence-Signature based on six specific CpG sites,
which seemed to display consistent SA-DNAm changes in different cell preparations. Two CpG
sites, associated with GRM7 and CASR genes, become continuously hyper-methylated in long-term
culture and four CpG sites, associated with PRAMEF2, SELP, CASP14, and KRTAP13-3 genes, become
hypo-methylated. Integration of these DNAm levels in linear-regression models facilitated prediction
of passage number, cumulative PD, and days of in vitro culture [114]. They further validated this
method on cell preparations isolated under good manufacturing practice (GMP) conditions, using
cells isolated in serial passages and with DNA directly extracted from cryopreserved samples [115].
The authors demonstrated that the epigenetic senescence signature reflected inter-individual
differences and variation in subpopulations, which are not necessarily mirrored in conventional
long-term growth curves [115]. In this regard, the cell epigenetic state might even provide the more
accurate measurement for cellular aging.
In conclusion, though to date there are no single effective methods to monitor in vitro hMSC
senescence and all proposed approaches present with some limitation, the evaluation of either gene
expression or DNA methylation profiles have recently provided powerful perspectives. Further
bioinformatic analyses of datasets and validation enrolling different MSC preparations will hopefully
pave the way for a reliable panel of distinct aging and senescence markers.
5. Tools to Prevent in Vitro hMSC Senescence
Some researchers have reported in vitro treatments that could improve hMSC performance.
Genetic engineering of cells is one possible approach for preventing in vitro aging. Some groups have
attempted to combat replicative senescence or improve MSC potency by induced ectopic expression
of telomerase [118,119]. However, this approach is inadvisable for clinical applications given the
possible risk of malignant transformation and/or induced tendency toward osteogenesis [120–122].
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Another strategy relied on RB silencing. In cells with silenced RB2, it was reported DNA damage,
apoptosis, and senescence reduction, along with proliferation rate and clonogenic ability, increase.
Cells with silenced RB2 were cultivated for extended periods without any signs of transformation;
however, silencing of RB genes disrupts differentiation to osteogenic, chondrogenic, and adipogenic
lineages [61].
Oxidative stress is one of the major insults accelerating cell senescence in vivo, as well as
in vitro [123]. Reduction of oxidative stress, by lowering oxygen tension or adding anti-oxidants,
such as vitamin C or N-acetylcysteine, has been shown to prolong replicative lifespan of human cells,
including hMSCs in vitro [124–127]. Isothiocyanates, reducing oxidative stress and protecting hMSCs
from chemically induced oxidative damage, may contribute to slowing the aging process related to
oxidative DNA damage [128]. Addition of 3% hydrogen gas to expansion cultures has been shown
to extend the replicative lifespan of MSCs while maintaining intact differentiation potential [129].
Notably, hydrogen gas treatment did not diminish paracrine activity of hMSCs, but slightly altered
the paracrine profiles. For example, hydrogen gas treatment increased both bFGF and HGF secretions
whereas it decreased Vascular Endothelial Growth Factor (VEGF) secretion [129].
Pharmacological approaches may also be employed as tools to prevent hMSC senescence in
culture. For example, decreased expression of histone deacetylases was observed in senescent MSCs;
consequently, the use of a histone acetyltransferase inhibitor prevented replicative senescence of
MSCs [130]. Additionally, lysophosphatidic acid (LPA), critical for membrane phospholipid synthesis,
has been shown to play a role in hMSC senescence, and pharmacologic antagonism of the LPA receptor
pathway achieved an anti-aging effect in cultured hMSCs, resulting in extended rounds of cellular
proliferation, increased clonogenic potential, and retained plasticity for osteogenic and adipogenic
differentiation [131].
It has been reported that inhibition of the phosphatidylinositol 3-kinase Akt/mTOR pathways
could provide an environment to maintain MSCs in their immature undifferentiated state during
long-term culture expansion. Human MSCs cultured in the presence of rapamycin showed morphology
of cells in their early passages, retained their clonogenic ability, and showed a high proliferative
rate and osteogenic potential. It was further demonstrated that loss of Akt/mTOR may mediate
these effects by regulating the production of cytoplasmic ROS, expression of pluripotency genes
Nanog and Oct-4, and by reducing accumulation of DNA damage during aging of MSCs [132].
Additionally, it has been demonstrated that rapamycin is also able influence the MSC senescent
inflammatory phenotype [133]. Authors showed that bone marrow-derived-MSCs from systemic
lupus erythematosus (SLE) patients exhibited senescent behaviour and were involved in the
pathogenesis of SLE. Rapamycin treatment was able to reverse the senescent phenotype and improved
immunoregulation. After transwell culture of CD4+ T cells with MSCs, the ratio of Treg/Th17
generated in the presence of the rapamycin-treated SLE MSCs was increased compared to those
cultured in the presence of the untreated SLE MSCs. Results showed that rapamycin-treatment
induced the secretion of IL-10 and TGF-β, two critical differentiation factors for the generation of
Treg cells [134]. On the other side, rapamycin-treatment downregulated IL-17 and IL-6, the main
factors involved in pro-inflammatory Th17 cell development [135]. Thus, their data demonstrated that
rapamycin improves the immunoregulatory capacity of MSCs from SLE patients and indicated the
involvement of the mTOR signalling pathway in the immune disorders of SLE patients [132].
The attempt to maintain hMSC self-renewal and differentiation potential through selected growth
factors and medium supplements leave limited success. In particular, medium supplementation
with fibroblast growth factor (FGF)-2, platelet-derived growth factor (PDGF)-BB, ascorbic acid (AA),
and epidermal growth factor (EGF) both increased proliferation rate and markedly increased number
of cell doublings before reaching senescence, with a greater than 1000-fold increase in total cell
numbers for AA, FGF-2, and PDGF-BB, compared with control cultures. However, long-term culture
was associated with loss of osteogenic/adipocytic differentiation potential, particularly with FGF-2
supplementation [136,137].
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Finally, many studies have reported successful derivation of functional MSCs from induced
pluripotent stem cells (iPSCs), referred to as induced MSCs (iMSCs) [138].The iMSCs are transpiring
as an attractive source of MSCs because, during reprogramming process, cells undergo rejuvination,
exhibiting better cellular vitality, such as survival, proliferation, and differentiation potentials [138].
The iMSCs could be easily scaled up to more than 40 passages while stably maintaining normal
diploid karyotype, and consistent gene expression and surface antigen profile [139]. Analogously,
Wei et al. demonstrated that human iMSCs could continuously proliferate for more than 32 passages
without undergoing cellular senescence and displayed superior wound healing and pro-angiogenic
properties [140]. Notably, the iMSCs retained donor-derived DNA methylation (DNAm) profile.
However, it is important to highlight that while tissue-specific and age-related DNAm profiles of iMSCs
were completely erased, the iMSCs reacquired SA-DNAm [141]. The same study also contrastingly
underlines that iMSCs reacquire incomplete immunomodulatory functions [141]. Eventually, the safety
of both viral and non-viral reprogramming strategies has to be taken in account for considering iPSCs
and the derived iMSCs as suitable candidates for biotherapeutics. Several challenges thus need to be
effectively tackled before iMSCs could be favourably used for translational applications.
Much further research is required to determine if such approaches could be safe and effective on
MSC-based cell therapy. Improving the conditions of ex vivo culture and discovering better markers
of MSC aging may help to suppress and monitor in vitro aging.
Acknowledgments: We would like to thank all of our past and present collaborators for their valuable contributions.
Author Contributions: Valentina Turinetto: paper conception and writing, figure preparation; Emanuela Vitale:
paper refinement, figure preparation; Claudia Giachino: paper conception and writing.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Crisan, M.; Yap, S.; Casteilla, L.; Chen, C.W.; Corselli, M.; Park, T.S.; Andriolo, G.; Sun, B.; Zheng, B.;
Zhang, L.; et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell
2008, 3, 301–313. [CrossRef] [PubMed]
2. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.;
Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International
Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317. [CrossRef] [PubMed]
3. Gebler, A.; Zabel, O.; Seliger, B. The immunomodulatory capacity of mesenchymal stem cells. TrendsMol. Med.
2012, 18, 128–134. [CrossRef] [PubMed]
4. Sharma, R.R.; Pollock, K.; Hubel, A.; McKenna, D. Mesenchymal stem or stromal cells: A review of clinical
applications and manufacturing practices. Transfusion 2014, 54, 1418–1437. [CrossRef] [PubMed]
5. Petrie Aronin, C.E.; Tuan, R.S. Therapeutic potential of the immunomodulatory activities of adult
mesenchymal stem cells. Birth Defects Res. C Embryo Today 2010, 90, 67–74. [CrossRef] [PubMed]
6. Wei, X.; Yang, X.; Han, Z.P.; Qu, F.F.; Shao, L.; Shi, Y.F. Mesenchymal stem cells: A new trend for cell therapy.
Acta Pharmacol. Sin. 2013, 34, 747–754. [CrossRef] [PubMed]
7. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 1965, 37, 614–636.
[CrossRef]
8. Sotiropoulou, P.A.; Perez, S.A.; Salagianni, M.; Baxevanis, C.N.; Papamichail, M. Characterization of the
optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006,
24, 462–471. [CrossRef] [PubMed]
9. Duggal, S.; Brinchmann, J.E. Importance of serum source for the in vitro replicative senescence of human
bone marrow derived mesenchymal stem cells. J. Cell. Physiol. 2011, 226, 2908–2915. [CrossRef] [PubMed]
10. Baker, N.; Boyette, L.B.; Tuan, R.S. Characterization of bone marrow-derived mesenchymal stem cells in
aging. Bone 2015, 70, 37–47. [CrossRef] [PubMed]
11. Ovadya, Y.; Krizhanovsky, V. Senescent cells: SASPected drivers of age-related pathologies. Biogerontology
2014, 15, 627–642. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 12 of 18
12. Velarde, M.C.; Demaria, M.; Campisi, J. Senescent cells and their secretory phenotype as targets for cancer
therapy. Interdiscip. Top. Gerontol. 2013, 38, 17–27. [PubMed]
13. Davalos, A.R.; Coppe, J.P.; Campisi, J.; Desprez, P.Y. Senescent cells as a source of inflammatory factors for
tumor progression. Cancer Metastasis Rev. 2010, 29, 273–283. [CrossRef] [PubMed]
14. Wang, Y.; Han, Z.B.; Song, Y.P.; Han, Z.C. Safety of mesenchymal stem cells for clinical application.
Stem Cells Int. 2012, 2012, 652034. [CrossRef] [PubMed]
15. D’Adda di Fagagna, F.; Reaper, P.M.; Clay-Farrace, L.; Fiegler, H.; Carr, P.; Von Zglinicki, T.; Saretzki, G.;
Carter, N.P.; Jackson, S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003,
426, 194–198. [CrossRef] [PubMed]
16. Takai, H.; Smogorzewska, A.; de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 2003, 13,
1549–1556. [CrossRef]
17. Herbig, U.; Jobling, W.A.; Chen, B.P.; Chen, D.J.; Sedivy, J.M. Telomere shortening triggers senescence of
human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14,
501–513. [CrossRef]
18. Rodier, F.; Coppe, J.P.; Patil, C.K.; Hoeijmakers, W.A.; Munoz, D.P.; Raza, S.R.; Freund, A.; Campeau, E.;
Davalos, A.R.; Campisi, J. Persistent DNA damage signalling triggers senescence-associated inflammatory
cytokine secretion. Nat. Cell Biol. 2009, 11, 973–979. [CrossRef] [PubMed]
19. Rodier, F.; Munoz, D.P.; Teachenor, R.; Chu, V.; Le, O.; Bhaumik, D.; Coppe, J.P.; Campeau, E.;
Beausejour, C.M.; Kim, S.H.; et al. DNA-SCARS: Distinct nuclear structures that sustain damage-induced
senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 2011, 124, 68–81. [CrossRef]
[PubMed]
20. Di Leonardo, A.; Linke, S.P.; Clarkin, K.; Wahl, G.M. DNA damage triggers a prolonged p53-dependent
G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994, 8, 2540–2551.
[CrossRef] [PubMed]
21. Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and
dimer dissociation. Nature 2003, 421, 499–506. [CrossRef] [PubMed]
22. Ogryzko, V.V.; Hirai, T.H.; Russanova, V.R.; Barbie, D.A.; Howard, B.H. Human fibroblast commitment to a
senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol. Cell. Biol.
1996, 16, 5210–5218. [CrossRef] [PubMed]
23. Munro, J.; Barr, N.I.; Ireland, H.; Morrison, V.; Parkinson, E.K. Histone deacetylase inhibitors induce a
senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock.
Exp. Cell Res. 2004, 295, 525–538. [CrossRef] [PubMed]
24. Serrano, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell
senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88, 593–602. [CrossRef]
25. Lin, A.W.; Barradas, M.; Stone, J.C.; van Aelst, L.; Serrano, M.; Lowe, S.W. Premature senescence involving
p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998, 12,
3008–3019. [CrossRef] [PubMed]
26. Zhu, J.; Woods, D.; McMahon, M.; Bishop, J.M. Senescence of human fibroblasts induced by oncogenic Raf.
Genes Dev. 1998, 12, 2997–3007. [CrossRef] [PubMed]
27. Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L.V.; Kolettas, E.;
Niforou, K.; Zoumpourlis, V.C.; et al. Oncogene-induced senescence is part of the tumorigenesis barrier
imposed by DNA damage checkpoints. Nature 2006, 444, 633–637. [CrossRef] [PubMed]
28. Di Micco, R.; Fumagalli, M.; Cicalese, A.; Piccinin, S.; Gasparini, P.; Luise, C.; Schurra, C.; Garre, M.;
Nuciforo, P.G.; Bensimon, A.; et al. Oncogene-induced senescence is a DNA damage response triggered by
DNA hyper-replication. Nature 2006, 444, 638–642. [CrossRef] [PubMed]
29. Mallette, F.A.; Gaumont-Leclerc, M.F.; Ferbeyre, G. The DNA damage signaling pathway is a critical mediator
of oncogene-induced senescence. Genes Dev. 2007, 21, 43–48. [CrossRef] [PubMed]
30. Chau, B.N.; Wang, J.Y. Coordinated regulation of life and death by RB. Nat. Rev. Cancer 2003, 3, 130–138.
[CrossRef] [PubMed]
31. Bargonetti, J.; Manfredi, J.J. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 2002, 14, 86–91.
[CrossRef] [PubMed]
32. Beausejour, C.M.; Krtolica, A.; Galimi, F.; Narita, M.; Lowe, S.W.; Yaswen, P.; Campisi, J. Reversal of human
cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 2003, 22, 4212–4222. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 13 of 18
33. Acosta, J.C.; O'Loghlen, A.; Banito, A.; Guijarro, M.V.; Augert, A.; Raguz, S.; Fumagalli, M.; Da Costa, M.;
Brown, C.; Popov, N.; et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008,
133, 1006–1018. [CrossRef] [PubMed]
34. Coppe, J.P.; Patil, C.K.; Rodier, F.; Sun, Y.; Munoz, D.P.; Goldstein, J.; Nelson, P.S.; Desprez, P.Y.; Campisi, J.
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the
p53 tumor suppressor. PLoS Biol. 2008, 6, 2853–2868. [CrossRef] [PubMed]
35. Coppe, J.P.; Patil, C.K.; Rodier, F.; Krtolica, A.; Beausejour, C.M.; Parrinello, S.; Hodgson, J.G.; Chin, K.;
Desprez, P.Y.; Campisi, J. A human-like senescence-associated secretory phenotype is conserved in mouse
cells dependent on physiological oxygen. PLoS ONE 2010, 5, e9188. [CrossRef] [PubMed]
36. Kuilman, T.; Michaloglou, C.; Vredeveld, L.C.; Douma, S.; van Doorn, R.; Desmet, C.J.; Aarden, L.A.;
Mooi, W.J.; Peeper, D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory
network. Cell 2008, 133, 1019–1031. [CrossRef] [PubMed]
37. Coppe, J.P.; Desprez, P.Y.; Krtolica, A.; Campisi, J. The senescence-associated secretory phenotype: The dark
side of tumor suppression. Annu. Rev. Pathol. 2010, 5, 99–118. [CrossRef] [PubMed]
38. Li, J.; Law, H.K.; Lau, Y.L.; Chan, G.C. Differential damage and recovery of human mesenchymal stem cells
after exposure to chemotherapeutic agents. Br. J. Haematol. 2004, 127, 326–334. [CrossRef] [PubMed]
39. Chen, M.F.; Lin, C.T.; Chen, W.C.; Yang, C.T.; Chen, C.C.; Liao, S.K.; Liu, J.M.; Lu, C.H.; Lee, K.D.
The sensitivity of human mesenchymal stem cells to ionizing radiation. Int. J. Radiat Oncol. Biol. Phys. 2006,
66, 244–253. [CrossRef] [PubMed]
40. Prendergast, A.M.; Cruet-Hennequart, S.; Shaw, G.; Barry, F.P.; Carty, M.P. Activation of DNA damage
response pathways in human mesenchymal stem cells exposed to cisplatin or γ-irradiation. Cell Cycle 2011,
10, 3768–3777. [CrossRef] [PubMed]
41. Oliver, L.; Hue, E.; Sery, Q.; Lafargue, A.; Pecqueur, C.; Paris, F.; Vallette, F.M. Differentiation-related response
to DNA breaks in human mesenchymal stem cells. Stem Cells 2013, 31, 800–807. [CrossRef] [PubMed]
42. Wang, D.; Jang, D.J. Protein kinase CK2 regulates cytoskeletal reorganization during ionizing
radiation-induced senescence of human mesenchymal stem cells. Cancer Res. 2009, 69, 8200–8207. [CrossRef]
[PubMed]
43. Kurpinski, K.; Jang, D.J.; Bhattacharya, S.; Rydberg, B.; Chu, J.; So, J.; Wyrobek, A.; Li, S.; Wang, D. Differential
effects of X-rays and high-energy 56Fe ions on human mesenchymal stem cells. Int. J. Radiat. Oncol. Biol. Phys.
2009, 73, 869–877. [CrossRef] [PubMed]
44. Cmielova, J.; Havelek, R.; Soukup, T.; Jiroutova, A.; Visek, B.; Suchanek, J.; Vavrova, J.; Mokry, J.; Muthna, D.;
Bruckova, L.; et al. γ radiation induces senescence in human adult mesenchymal stem cells from bone
marrow and periodontal ligaments. Int. J. Radiat. Biol. 2012, 88, 393–404. [CrossRef] [PubMed]
45. Muthna, D.; Soukup, T.; Vavrova, J.; Mokry, J.; Cmielova, J.; Visek, B.; Jiroutova, A.; Havelek, R.; Suchanek, J.;
Filip, S.; et al. Irradiation of adult human dental pulp stem cells provokes activation of p53, cell cycle arrest,
and senescence but not apoptosis. Stem Cells Dev. 2010, 19, 1855–1862. [CrossRef] [PubMed]
46. Seifrtova, M.; Havelek, R.; Soukup, T.; Filipova, A.; Mokry, J.; Rezacova, M. Mitoxantrone ability to induce
premature senescence in human dental pulp stem cells and human dermal fibroblasts. J. Physiol. Pharmacol.
2013, 64, 255–266. [PubMed]
47. Ko, E.; Lee, K.Y.; Hwang, D.S. Human umbilical cord blood-derived mesenchymal stem cells undergo
cellular senescence in response to oxidative stress. Stem Cells Dev. 2012, 21, 1877–1886. [CrossRef] [PubMed]
48. Alekseenko, L.L.; Zemelko, V.I.; Domnina, A.P.; Lyublinskaya, O.G.; Zenin, V.V.; Pugovkina, N.A.;
Kozhukharova, I.V.; Borodkina, A.V.; Grinchuk, T.M.; Fridlyanskaya, I.I.; et al. Sublethal heat shock induces
premature senescence rather than apoptosis in human mesenchymal stem cells. Cell Stress Chaperones 2014,
19, 355–366. [CrossRef] [PubMed]
49. Burova, E.; Borodkina, A.; Shatrova, A.; Nikolsky, N. Sublethal oxidative stress induces the premature
senescence of human mesenchymal stem cells derived from endometrium. Oxid. Med. Cell. Longev. 2013,
2013, 474931. [CrossRef] [PubMed]
50. Kim, J.S.; Kim, E.J.; Kim, H.J.; Yang, J.Y.; Hwang, G.S.; Kim, C.W. Proteomic and metabolomic analysis
of H2O2-induced premature senescent human mesenchymal stem cells. Exp. Gerontol. 2011, 46, 500–510.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 14 of 18
51. Minieri, V.; Saviozzi, S.; Gambarotta, G.; Lo Iacono, M.; Accomasso, L.; Cibrario Rocchietti, E.; Gallina, C.;
Turinetto, V.; Giachino, C. Persistent DNA damage-induced premature senescence alters the functional
features of human bone marrow mesenchymal stem cells. J. Cell. Mol. Med. 2015, 19, 734–743. [CrossRef]
[PubMed]
52. Skolekova, S.; Matuskova, M.; Bohac, M.; Toro, L.; Demkova, L.; Gursky, J.; Kucerova, L. Cisplatin-induced
mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer
cells. Cell Commun. Signal. 2016, 14, 4. [CrossRef] [PubMed]
53. Sepulveda, J.C.; Tome, M.; Fernandez, M.E.; Delgado, M.; Campisi, J.; Bernad, A.; Gonzalez, M.A. Cell
senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia
model. Stem Cells 2014, 32, 1865–1877. [CrossRef] [PubMed]
54. Wagner, W.; Horn, P.; Castoldi, M.; Diehlmann, A.; Bork, S.; Saffrich, R.; Benes, V.; Blake, J.; Pfister, S.;
Eckstein, V.; et al. Replicative senescence of mesenchymal stem cells: A continuous and organized process.
PLoS ONE 2008, 3, e2213. [CrossRef] [PubMed]
55. Geissler, S.; Textor, M.; Kuhnisch, J.; Konnig, D.; Klein, O.; Ode, A.; Pfitzner, T.; Adjaye, J.; Kasper, G.;
Duda, G.N. Functional comparison of chronological and in vitro aging: Differential role of the cytoskeleton
and mitochondria in mesenchymal stromal cells. PLoS ONE 2012, 7, e52700.
56. He, L.; He, X.; Lim, L.P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; et al.
A microRNA component of the p53 tumour suppressor network. Nature 2007, 447, 1130–1134. [CrossRef]
[PubMed]
57. Tazawa, H.; Kagawa, S.; Fujiwara, T. MicroRNAs as potential target gene in cancer gene therapy of
gastrointestinal tumors. Expert Opin. Biol. Ther. 2011, 11, 145–155. [CrossRef] [PubMed]
58. Hackl, M.; Brunner, S.; Fortschegger, K.; Schreiner, C.; Micutkova, L.; Muck, C.; Laschober, G.T.;
Lepperdinger, G.; Sampson, N.; Berger, P.; et al. miR-17, miR-19b, miR-20a, and miR-106a are down-regulated
in human aging. Aging Cell 2010, 9, 291–296. [CrossRef] [PubMed]
59. Wagner, W.; Bork, S.; Horn, P.; Krunic, D.; Walenda, T.; Diehlmann, A.; Benes, V.; Blake, J.; Huber, F.X.;
Eckstein, V.; et al. Aging and replicative senescence have related effects on human stem and progenitor cells.
PLoS ONE 2009, 4, e5846. [CrossRef] [PubMed]
60. Cheng, H.; Qiu, L.; Ma, J.; Zhang, H.; Cheng, M.; Li, W.; Zhao, X.; Liu, K. Replicative senescence of human
bone marrow and umbilical cord derived mesenchymal stem cells and their differentiation to adipocytes
and osteoblasts. Mol. Biol. Rep. 2011, 38, 5161–5168. [CrossRef] [PubMed]
61. Alessio, N.; Bohn, W.; Rauchberger, V.; Rizzolio, F.; Cipollaro, M.; Rosemann, M.; Irmler, M.; Beckers, J.;
Giordano, A.; Galderisi, U. Silencing of RB1 but not of RB2/P130 induces cellular senescence and impairs
the differentiation potential of human mesenchymal stem cells. Cell. Mol. Life Sci. 2013, 70, 1637–1651.
[CrossRef] [PubMed]
62. Banfi, A.; Muraglia, A.; Dozin, B.; Mastrogiacomo, M.; Cancedda, R.; Quarto, R. Proliferation kinetics and
differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in
cell therapy. Exp. Hematol. 2000, 28, 707–715. [CrossRef]
63. Bruder, S.P.; Jaiswal, N.; Haynesworth, S.E. Growth kinetics, self-renewal, and the osteogenic potential of
purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation.
J. Cell. Biochem. 1997, 64, 278–294. [CrossRef]
64. Digirolamo, C.M.; Stokes, D.; Colter, D.; Phinney, D.G.; Class, R.; Prockop, D.J. Propagation and senescence of
human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest
potential to propagate and differentiate. Br. J. Haematol. 1999, 107, 275–281. [CrossRef] [PubMed]
65. Kim, M.; Kim, C.; Choi, Y.S.; Park, C.; Suh, Y. Age-related alterations in mesenchymal stem cells related to
shift in differentiation from osteogenic to adipogenic potential: Implication to age-associated bone diseases
and defects. Mech Ageing Dev. 2012, 133, 215–225. [CrossRef] [PubMed]
66. Baggiolini, M.; Clark-Lewis, I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992, 307,
97–101. [CrossRef]
67. Li, A.; Dubey, S.; Varney, M.L.; Dave, B.J.; Singh, R.K. IL-8 directly enhanced endothelial cell survival,
proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 2003, 170,
3369–3376. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 15 of 18
68. Spronk, P.E.; Bootsma, H.; Huitema, M.G.; Limburg, P.C.; Kallenberg, C.G. Levels of soluble VCAM-1, soluble
ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus
(SLE); a long term prospective study. Clin. Exp. Immunol. 1994, 97, 439–444. [CrossRef] [PubMed]
69. Blankenberg, S.; Rupprecht, H.J.; Bickel, C.; Peetz, D.; Hafner, G.; Tiret, L.; Meyer, J. Circulating cell adhesion
molecules and death in patients with coronary artery disease. Circulation 2001, 104, 1336–1342. [CrossRef]
[PubMed]
70. Tanuma, N.; Sakuma, H.; Sasaki, A.; Matsumoto, Y. Chemokine expression by astrocytes plays a role in
microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple
sclerosis. Acta Neuropathol. 2006, 112, 195–204. [CrossRef] [PubMed]
71. Spoettl, T.; Hausmann, M.; Herlyn, M.; Gunckel, M.; Dirmeier, A.; Falk, W.; Herfarth, H.; Schoelmerich, J.;
Rogler, G. Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of
monocytes. Clin. Exp. Immunol. 2006, 145, 190–199. [CrossRef] [PubMed]
72. Gallina, C.; Turinetto, V.; Giachino, C. A new paradigm in cardiac regeneration: The mesenchymal stem cell
secretome. Stem Cells Int. 2015, 2015, 765846. [CrossRef] [PubMed]
73. Liang, X.; Ding, Y.; Zhang, Y.; Tse, H.F.; Lian, Q. Paracrine mechanisms of mesenchymal stem cell-based
therapy: Current status and perspectives. Cell Transplant. 2014, 23, 1045–1059. [CrossRef] [PubMed]
74. Tome, M.; Sepulveda, J.C.; Delgado, M.; Andrades, J.A.; Campisi, J.; Gonzalez, M.A.; Bernad, A. miR-335
correlates with senescence/aging in human mesenchymal stem cells and inhibits their therapeutic actions
through inhibition of AP-1 activity. Stem Cells 2014, 32, 2229–2244. [CrossRef] [PubMed]
75. Kasper, G.; Mao, L.; Geissler, S.; Draycheva, A.; Trippens, J.; Kuhnisch, J.; Tschirschmann, M.; Kaspar, K.;
Perka, C.; Duda, G.N.; et al. Insights into mesenchymal stem cell aging: Involvement of antioxidant defense
and actin cytoskeleton. Stem Cells 2009, 27, 1288–1297. [CrossRef] [PubMed]
76. Jung, E.M.; Kwon, O.; Kwon, K.S.; Cho, Y.S.; Rhee, S.K.; Min, J.K.; Oh, D.B. Evidences for correlation
between the reduced VCAM-1 expression and hyaluronan synthesis during cellular senescence of human
mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2011, 404, 463–469. [CrossRef] [PubMed]
77. Rombouts, W.J.; Ploemacher, R.E. Primary murine MSC show highly efficient homing to the bone marrow
but lose homing ability following culture. Leukemia 2003, 17, 160–170. [CrossRef] [PubMed]
78. Le Clainche, C.; Carlier, M.F. Regulation of actin assembly associated with protrusion and adhesion in cell
migration. Physiol. Rev. 2008, 88, 489–513. [CrossRef] [PubMed]
79. Larsen, M.; Tremblay, M.L.; Yamada, K.M. Phosphatases in cell-matrix adhesion and migration. Nat. Rev.
Mol. Cell Biol. 2003, 4, 700–711. [CrossRef] [PubMed]
80. Kretlow, J.D.; Jin, Y.Q.; Liu, W.; Zhang, W.J.; Hong, T.H.; Zhou, G.; Baggett, L.S.; Mikos, A.G.; Cao, Y.
Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells.
BMC Cell Biol. 2008, 9, 60. [CrossRef] [PubMed]
81. Kitaori, T.; Ito, H.; Schwarz, E.M.; Tsutsumi, R.; Yoshitomi, H.; Oishi, S.; Nakano, M.; Fujii, N.; Nagasawa, T.;
Nakamura, T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal
stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009, 60, 813–823.
[CrossRef] [PubMed]
82. Rodier, F.; Campisi, J.; Bhaumik, D. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res. 2007,
35, 7475–7484. [CrossRef] [PubMed]
83. Krtolica, A.; Parrinello, S.; Lockett, S.; Desprez, P.Y.; Campisi, J. Senescent fibroblasts promote epithelial
cell growth and tumorigenesis: A link between cancer and aging. Proc. Natl. Acad. Sci. USA 2001, 98,
12072–12077. [CrossRef] [PubMed]
84. Coppe, J.P.; Kauser, K.; Campisi, J.; Beausejour, C.M. Secretion of vascular endothelial growth factor by
primary human fibroblasts at senescence. J. Biol. Chem. 2006, 281, 29568–29574. [CrossRef] [PubMed]
85. Coppe, J.P.; Boysen, M.; Sun, C.H.; Wong, B.J.; Kang, M.K.; Park, N.H.; Desprez, P.Y.; Campisi, J.; Krtolica, A.
A role for fibroblasts in mediating the effects of tobacco-induced epithelial cell growth and invasion.
Mol. Cancer Res. 2008, 6, 1085–1098. [CrossRef] [PubMed]
86. Liu, D.; Hornsby, P.J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix
metalloproteinase secretion. Cancer Res. 2007, 67, 3117–3126. [CrossRef] [PubMed]
87. Acosta, J.C.; O'Loghlen, A.; Banito, A.; Raguz, S.; Gil, J. Control of senescence by CXCR2 and its ligands.
Cell Cycle 2008, 7, 2956–2959. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 16 of 18
88. Klopp, A.H.; Gupta, A.; Spaeth, E.; Andreeff, M.; Marini, F., 3rd. Concise review: Dissecting a discrepancy in
the literature: Do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011, 29, 11–19.
[CrossRef] [PubMed]
89. Littlepage, L.E.; Egeblad, M.; Werb, Z. Coevolution of cancer and stromal cellular responses. Cancer Cell
2005, 7, 499–500. [CrossRef] [PubMed]
90. Zhu, W.; Huang, L.; Li, Y.; Qian, H.; Shan, X.; Yan, Y.; Mao, F.; Wu, X.; Xu, W.R. Mesenchymal stem
cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle 2011, 10, 3198–3207. [CrossRef]
[PubMed]
91. Li, Y.; Xu, X.; Wang, L.; Liu, G.; Wu, X.; Jing, Y.; Li, H.; Wang, G. Senescent mesenchymal stem cells promote
colorectal cancer cells growth via galectin-3 expression. Cell Biosci. 2015, 5, 21. [CrossRef] [PubMed]
92. Di, G.H.; Liu, Y.; Lu, Y.; Liu, J.; Wu, C.; Duan, H.F. IL-6 secreted from senescent mesenchymal stem cells
promotes proliferation and migration of breast cancer cells. PLoS ONE 2014, 9, e113572. [CrossRef] [PubMed]
93. Ruvolo, P.P. Galectin 3 as a guardian of the tumor microenvironment. Biochim. Biophys. Acta 2016, 1863,
427–437. [CrossRef] [PubMed]
94. Wagner, W.; Ho, A.D. Mesenchymal stem cell preparations—Comparing apples and oranges. Stem Cell Rev.
2007, 3, 239–248. [CrossRef] [PubMed]
95. Wagner, W.; Ho, A.D.; Zenke, M. Different facets of aging in human mesenchymal stem cells. Tissue Eng.
Part B Rev. 2010, 16, 445–453. [CrossRef] [PubMed]
96. Larson, B.L.; Ylostalo, J.; Prockop, D.J. Human multipotent stromal cells undergo sharp transition from
division to development in culture. Stem Cells 2008, 26, 193–201. [CrossRef] [PubMed]
97. Bartmann, C.; Rohde, E.; Schallmoser, K.; Purstner, P.; Lanzer, G.; Linkesch, W.; Strunk, D. Two steps to
functional mesenchymal stromal cells for clinical application. Transfusion 2007, 47, 1426–1435. [CrossRef]
[PubMed]
98. Cristofalo, V.J.; Allen, R.G.; Pignolo, R.J.; Martin, B.G.; Beck, J.C. Relationship between donor age and
the replicative lifespan of human cells in culture: A reevaluation. Proc. Natl. Acad. Sci. USA 1998, 95,
10614–10619. [CrossRef] [PubMed]
99. Zhou, S.; Greenberger, J.S.; Epperly, M.W.; Goff, J.P.; Adler, C.; Leboff, M.S.; Glowacki, J. Age-related intrinsic
changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts.
Aging Cell 2008, 7, 335–343. [CrossRef] [PubMed]
100. Harley, C.B.; Futcher, A.B.; Greider, C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990,
345, 458–460. [CrossRef] [PubMed]
101. Tarte, K.; Gaillard, J.; Lataillade, J.J.; Fouillard, L.; Becker, M.; Mossafa, H.; Tchirkov, A.; Rouard, H.;
Henry, C.; Splingard, M.; et al. Clinical-grade production of human mesenchymal stromal cells: Occurrence
of aneuploidy without transformation. Blood 2010, 115, 1549–1553. [CrossRef] [PubMed]
102. Ben-David, U.; Mayshar, Y.; Benvenisty, N. Large-scale analysis reveals acquisition of lineage-specific
chromosomal aberrations in human adult stem cells. Cell Stem Cell 2011, 9, 97–102. [CrossRef] [PubMed]
103. Ueyama, H.; Horibe, T.; Hinotsu, S.; Tanaka, T.; Inoue, T.; Urushihara, H.; Kitagawa, A.; Kawakami, K.
Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. J. Cell.
Mol. Med. 2012, 16, 72–82. [CrossRef] [PubMed]
104. Estrada, J.C.; Torres, Y.; Benguria, A.; Dopazo, A.; Roche, E.; Carrera-Quintanar, L.; Perez, R.A.; Enriquez, J.A.;
Torres, R.; Ramirez, J.C.; et al. Human mesenchymal stem cell-replicative senescence and oxidative stress are
closely linked to aneuploidy. Cell Death Dis. 2013, 4, e691. [CrossRef] [PubMed]
105. Redaelli, S.; Bentivegna, A.; Foudah, D.; Miloso, M.; Redondo, J.; Riva, G.; Baronchelli, S.; Dalpra, L.;
Tredici, G. From cytogenomic to epigenomic profiles: Monitoring the biologic behavior of in vitro cultured
human bone marrow mesenchymal stem cells. Stem Cell Res. Ther. 2012, 3, 47. [CrossRef] [PubMed]
106. Lucarelli, E.; Bellotti, C.; Mantelli, M.; Avanzini, M.A.; Maccario, R.; Novara, F.; Arrigo, G.; Zuffardi, O.;
Zuntini, M.; Pandolfi, M.; et al. In vitro biosafety profile evaluation of multipotent mesenchymal stem cells
derived from the bone marrow of sarcoma patients. J. Transl. Med. 2014, 12, 95. [CrossRef] [PubMed]
107. Schallmoser, K.; Bartmann, C.; Rohde, E.; Bork, S.; Guelly, C.; Obenauf, A.C.; Reinisch, A.; Horn, P.; Ho, A.D.;
Strunk, D.; et al. Replicative senescence-associated gene expression changes in mesenchymal stromal cells
are similar under different culture conditions. Haematologica 2010, 95, 867–874. [CrossRef] [PubMed]
108. Wagner, W.; Bork, S.; Lepperdinger, G.; Joussen, S.; Ma, N.; Strunk, D.; Koch, C. How to track cellular aging
of mesenchymal stromal cells? Aging 2010, 2, 224–230. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 17 of 18
109. Bellayr, I.H.; Catalano, J.G.; Lababidi, S.; Yang, A.X.; Lo Surdo, J.L.; Bauer, S.R.; Puri, R.K. Gene markers
of cellular aging in human multipotent stromal cells in culture. Stem Cell Res. Ther. 2014, 5, 59. [CrossRef]
[PubMed]
110. Kulterer, B.; Friedl, G.; Jandrositz, A.; Sanchez-Cabo, F.; Prokesch, A.; Paar, C.; Scheideler, M.; Windhager, R.;
Preisegger, K.H.; Trajanoski, Z. Gene expression profiling of human mesenchymal stem cells derived from
bone marrow during expansion and osteoblast differentiation. BMC Genom. 2007, 8, 70. [CrossRef] [PubMed]
111. Tanabe, S.; Sato, Y.; Suzuki, T.; Suzuki, K.; Nagao, T.; Yamaguchi, T. Gene expression profiling of human
mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture. J. Biochem.
2008, 144, 399–408. [CrossRef] [PubMed]
112. Bork, S.; Pfister, S.; Witt, H.; Horn, P.; Korn, B.; Ho, A.D.; Wagner, W. DNA methylation pattern changes upon
long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010, 9, 54–63. [CrossRef]
[PubMed]
113. Choi, M.R.; In, Y.H.; Park, J.; Park, T.; Jung, K.H.; Chai, J.C.; Chung, M.K.; Lee, Y.S.; Chai, Y.G. Genome-scale
DNA methylation pattern profiling of human bone marrow mesenchymal stem cells in long-term culture.
Exp. Mol. Med. 2012, 44, 503–512. [CrossRef] [PubMed]
114. Koch, C.M.; Joussen, S.; Schellenberg, A.; Lin, Q.; Zenke, M.; Wagner, W. Monitoring of cellular senescence
by DNA-methylation at specific CpG sites. Aging Cell 2012, 11, 366–369. [CrossRef] [PubMed]
115. Schellenberg, A.; Mauen, S.; Koch, C.M.; Jans, R.; de Waele, P.; Wagner, W. Proof of principle: Quality control
of therapeutic cell preparations using senescence-associated DNA-methylation changes. BMC Res. Notes
2014, 7, 254. [CrossRef] [PubMed]
116. Shay, J.W.; Zou, Y.; Hiyama, E.; Wright, W.E. Telomerase and cancer. Hum. Mol. Genet. 2001, 10, 677–685.
[CrossRef] [PubMed]
117. Izadpanah, R.; Kaushal, D.; Kriedt, C.; Tsien, F.; Patel, B.; Dufour, J.; Bunnell, B.A. Long-term in vitro
expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008, 68, 4229–4238. [CrossRef]
[PubMed]
118. Park, I.H.; Zhao, R.; West, J.A.; Yabuuchi, A.; Huo, H.; Ince, T.A.; Lerou, P.H.; Lensch, M.W.; Daley, G.Q.
Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451, 141–146.
[CrossRef] [PubMed]
119. Tang, H.; Xiang, Y.; Jiang, X.; Ke, Y.; Xiao, Z.; Guo, Y.; Wang, Q.; Du, M.; Qin, L.; Zou, Y.; et al. Dual expression
of hTERT and VEGF prolongs life span and enhances angiogenic ability of aged BMSCs. Biochem. Biophys.
Res. Commun. 2013, 440, 502–508. [CrossRef] [PubMed]
120. Gronthos, S.; Chen, S.; Wang, C.Y.; Robey, P.G.; Shi, S. Telomerase accelerates osteogenesis of bone marrow
stromal stem cells by upregulation of CBFA1, osterix, and osteocalcin. J. Bone Miner. Res. 2003, 18, 716–722.
[CrossRef] [PubMed]
121. Simonsen, J.L.; Rosada, C.; Serakinci, N.; Justesen, J.; Stenderup, K.; Rattan, S.I.; Jensen, T.G.; Kassem, M.
Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human
bone marrow stromal cells. Nat. Biotechnol. 2002, 20, 592–596. [CrossRef] [PubMed]
122. Shi, S.; Gronthos, S.; Chen, S.; Reddi, A.; Counter, C.M.; Robey, P.G.; Wang, C.Y. Bone formation by human
postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat. Biotechnol. 2002, 20,
587–591. [CrossRef] [PubMed]
123. Campisi, J. From cells to organisms: Can we learn about aging from cells in culture? Exp. Gerontol. 2001, 36,
607–618. [CrossRef]
124. Kashino, G.; Kodama, S.; Nakayama, Y.; Suzuki, K.; Fukase, K.; Goto, M.; Watanabe, M. Relief of oxidative
stress by ascorbic acid delays cellular senescence of normal human and Werner syndrome fibroblast cells.
Free Radic. Biol. Med. 2003, 35, 438–443. [CrossRef]
125. Fehrer, C.; Brunauer, R.; Laschober, G.; Unterluggauer, H.; Reitinger, S.; Kloss, F.; Gully, C.; Gassner, R.;
Lepperdinger, G. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem
cells and prolongs their lifespan. Aging Cell 2007, 6, 745–757. [CrossRef] [PubMed]
126. Lin, T.M.; Tsai, J.L.; Lin, S.D.; Lai, C.S.; Chang, C.C. Accelerated growth and prolonged lifespan of adipose
tissue-derived human mesenchymal stem cells in a medium using reduced calcium and antioxidants.
Stem Cells Dev. 2005, 14, 92–102. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1164 18 of 18
127. Jin, Y.; Kato, T.; Furu, M.; Nasu, A.; Kajita, Y.; Mitsui, H.; Ueda, M.; Aoyama, T.; Nakayama, T.; Nakamura, T.;
et al. Mesenchymal stem cells cultured under hypoxia escape from senescence via down-regulation of p16
and extracellular signal regulated kinase. Biochem. Biophys. Res. Commun. 2010, 391, 1471–1476. [CrossRef]
[PubMed]
128. Zanichelli, F.; Capasso, S.; Di Bernardo, G.; Cipollaro, M.; Pagnotta, E.; Carteni, M.; Casale, F.; Iori, R.;
Giordano, A.; Galderisi, U. Low concentrations of isothiocyanates protect mesenchymal stem cells from
oxidative injuries, while high concentrations exacerbate DNA damage. Apoptosis 2012, 17, 964–974.
[CrossRef] [PubMed]
129. Kawasaki, H.; Guan, J.; Tamama, K. Hydrogen gas treatment prolongs replicative lifespan of bone
marrow multipotential stromal cells in vitro while preserving differentiation and paracrine potentials.
Biochem. Biophys. Res. Commun. 2010, 397, 608–613. [CrossRef] [PubMed]
130. Jung, J.W.; Lee, S.; Seo, M.S.; Park, S.B.; Kurtz, A.; Kang, S.K.; Kang, K.S. Histone deacetylase controls adult
stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell. Mol.
Life Sci. 2010, 67, 1165–1176. [CrossRef] [PubMed]
131. Kanehira, M.; Kikuchi, T.; Ohkouchi, S.; Shibahara, T.; Tode, N.; Santoso, A.; Daito, H.; Ohta, H.; Tamada, T.;
Nukiwa, T. Targeting lysophosphatidic acid signaling retards culture-associated senescence of human
marrow stromal cells. PLoS ONE 2012, 7, e32185. [CrossRef] [PubMed]
132. Gharibi, B.; Farzadi, S.; Ghuman, M.; Hughes, F.J. Inhibition of Akt/mTOR attenuates age-related changes in
mesenchymal stem cells. Stem Cells 2014, 32, 2256–2266. [CrossRef] [PubMed]
133. Gu, Z.; Tan, W.; Ji, J.; Feng, G.; Meng, Y.; Da, Z.; Guo, G.; Xia, Y.; Zhu, X.; Shi, G.; et al. Rapamycin reverses
the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/LPR mice
and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. Aging 2016,
8, 1102–1114. [CrossRef] [PubMed]
134. Mills, K.H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 2008, 38, 2636–2649.
[CrossRef] [PubMed]
135. Zhao, R. Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis. Eur. J.
Clin. Investig. 2013, 43, 1195–1202. [CrossRef] [PubMed]
136. Gharibi, B.; Hughes, F.J. Effects of medium supplements on proliferation, differentiation potential, and
in vitro expansion of mesenchymal stem cells. Stem Cells Transl. Med. 2012, 1, 771–782. [CrossRef] [PubMed]
137. Coutu, D.L.; Francois, M.; Galipeau, J. Inhibition of cellular senescence by developmentally regulated FGF
receptors in mesenchymal stem cells. Blood 2011, 117, 6801–6812. [CrossRef] [PubMed]
138. Sabapathy, V.; Kumar, S. hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell
resource for regenerative medicine. J. Cell. Mol. Med. 2016. [CrossRef] [PubMed]
139. Lian, Q.; Zhang, Y.; Zhang, J.; Zhang, H.K.; Wu, X.; Lam, F.F.; Kang, S.; Xia, J.C.; Lai, W.H.; Au, K.W.; et al.
Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb
ischemia in mice. Circulation 2010, 121, 1113–1123. [CrossRef] [PubMed]
140. Wei, H.; Tan, G.; Manasi; Qiu, S.; Kong, G.; Yong, P.; Koh, C.; Ooi, T.H.; Lim, S.Y.; Wong, P.; et al. One-step
derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells. Stem Cell Res.
2012, 9, 87–100. [CrossRef] [PubMed]
141. Frobel, J.; Hemeda, H.; Lenz, M.; Abagnale, G.; Joussen, S.; Denecke, B.; Saric, T.; Zenke, M.; Wagner, W.
Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells.
Stem Cell Rep. 2014, 3, 414–422. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
